Recently, there have been numerous advances in the biological understanding of ovarian cancer. At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December 2015, Jonathan A. Ledermann, BSc, MD, FRCP, from UCL Cancer Institute and UCL Hospitals, London UK, discusses the therapeutic development and impact of olaparib, a poly(ADP-ribose) polymerase (PARP) inhibitor, for the management of patients with BRCA-related ovarian cancer.
Olaparib: An opportunity for personalised medicine in BRCA-related ovarian cancer
4th February 2016
Keep your finger on the pulseJoin Now
Elevating the Quality of Healthcare Globally